PTMA and neoplasm: To further investigate the anti-tumor activity of neoantigen peptides, these 7 neoantigen peptides were further mixed with an optimized clinically available dual immune adjuvant [Poly(I:C) and thymosin alpha-1] to prepare personalized neoantigen vaccine for LLC (LLCvac).